close
Add to watchlist
Lannett Co Inc (LCI) Healthcare, Biotechnology & Drugs
Lannett Company, Inc. develops, manufactures, markets, and distributes generic versions of pharmaceutical products in the United States. Its products portfolio primarily includes Acetazolamide tablets for glaucoma; Baclofen tablets for muscle relaxation; Bethanechol Chloride tablets for urinary retention; Butalbital, Aspirin, Caffeine with Codeine Phosphate capsules to treat migraine headache; Clindamycin HCl capsules, Doxycycline tablets, Doxycycline Hyclate tablets used as antibiotics; Danazol capsules for endometriosis; Dicyclomine tablets/capsules for irritable bowels; Digoxin tablets to treat congestive heart failure; and Diphenoxylate with Atropine Sulfate tablets for Diarrhea. The company also offers Hydromorphone HCl tablets, Morphine Sulfate oral solution, and Oxycodone HCl oral solution for pain management; Levothyroxine Sodium tablets to treat thyroid deficiency; Methyltestoterone/Esterified Estrogens tablets used in hormone replacement; Phentermine HCl tablets/capsules for weight loss; Pilocarpine HCl tablets to treat dryness of the mouth; Primidone tablets for epilepsy; Probenecid tablets for gout; Sulfamethoxazole with Trimethoprim used as antibacterial; Terbutaline Sulfate tablets for bronchospasms; and Unithroid tablets to treat thyroid deficiency. Lannett Company sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, and health maintenance organizations. It has supply and development agreements with Olive Healthcare of India; Orion Pharma of Finland; Azad Pharma AG of Switzerland; Unichem, Inc. of India; Wintac Limited of India; Pharmaseed in Israel; and Banner Pharmacaps and Catalent of the United States. The company was founded in 1942 and is based in Philadelphia, Pennsylvania.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 4.44 |
| Volume | 20176 |
| Volume Avg | 37457 |
| 52 Week High | 5.89 |
| 52 Week Low | 3.41 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.05 |
| EPS change Q/Q | 1000% |
| EPS change Q/Q Yr ago | 1000% |
| EPS change Q/Q next Q est | 1000% |
| EPS change Y/Y | 76.47% |
| REV change Q/Q | -13.67% |
| REV change Q/Q Yr ago | -17.25% |
| EPS next Q est | 0.06 |
| EPS next Y est | 0.35 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |